Versartis (NASDAQ:VSAR) will announce its earnings results after the market closes on Wednesday, February 21st. Analysts expect the company to announce earnings of ($0.97) per share for the quarter.
Shares of Versartis (NASDAQ VSAR) opened at $1.70 on Monday. Versartis has a 52 week low of $1.60 and a 52 week high of $24.00. The stock has a market capitalization of $60.88, a PE ratio of -0.43 and a beta of 2.11. The company has a quick ratio of 1.52, a current ratio of 1.52 and a debt-to-equity ratio of 0.11.
In other Versartis news, insider Jay Shepard sold 14,446 shares of Versartis stock in a transaction dated Thursday, February 8th. The stock was sold at an average price of $1.80, for a total transaction of $26,002.80. Following the completion of the transaction, the insider now owns 602,298 shares of the company’s stock, valued at approximately $1,084,136.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Srinivas Akkaraju bought 513,872 shares of Versartis stock in a transaction on Monday, December 4th. The shares were bought at an average cost of $2.21 per share, with a total value of $1,135,657.12. Following the acquisition, the director now directly owns 14,955 shares in the company, valued at $33,050.55. The disclosure for this purchase can be found here. Insiders have sold a total of 21,400 shares of company stock valued at $38,520 in the last ninety days. Insiders own 10.90% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This report was originally reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this report on another publication, it was illegally copied and reposted in violation of United States & international trademark & copyright laws. The legal version of this report can be viewed at https://stocknewstimes.com/2018/02/19/versartis-vsar-to-release-earnings-on-wednesday-2.html.
Versartis Company Profile
Versartis, Inc is an endocrine-focused biopharmaceutical company. The Company is engaged in developing a long-acting form of recombinant human growth hormone, somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company’s first indication for somavaratan is pediatric GHD.
Receive News & Ratings for Versartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Versartis and related companies with MarketBeat.com's FREE daily email newsletter.